Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | Becton Dickinson and Co | 242 |
| 2 | F Hoffmann La Roche AG | 214 |
| 3 | 10X Genomics Inc | 174 |
| 4 | University of California, San Diego | 143 |
| 5 | Harvard University | 132 |
| 6 | Leland Stanford Junior University | 117 |
| 7 | Regeneron Pharmaceuticals Inc | 114 |
| 8 | Institut National de la Santé et de la Recherche Médicale | 103 |
| 9 | Amgen Inc | 100 |
| 10 | Massachusetts Institute of Technology | 96 |
Explore the full landscape
This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.
Visit CyprisWhere innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | A61K | Medicinal preparations | 7,063 |
| 2 | A61P | Therapeutic activity (drug indications) | 6,084 |
| 3 | C07K | Peptides | 5,054 |
| 4 | C12N | Microorganisms, enzymes | 4,011 |
| 5 | G01N | Investigating / analysing materials | 3,550 |
| 6 | C12Q | Measuring/testing involving enzymes | 3,021 |
| 7 | Y02A | Climate change adaptation | 1,064 |
| 8 | C07D | Heterocyclic compounds | 614 |
| 9 | C12Y | Enzyme nomenclature (EC numbers) | 439 |
| 10 | B01L | 303 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionMost-cited patents
Patents ranked by forward citations reveal the foundational inventions the field continues to build on.
| Title | Year | Assignee | Cited by |
|---|---|---|---|
| CY5.5 carboxylic acid marked heat shock protein 90-II type fluorescent probe, preparation method and application thereof | 2025 | AFFILIATED HOSPITAL OF GUANGDONG MEDICAL UNIVERSITY | 0 |
| Heat shock protein 90-I type fluorescent probe coupled with CY5.5 carboxylic acid, preparation method and application thereof | 2025 | AFFILIATED HOSPITAL OF GUANGDONG MEDICAL UNIVERSITY | 0 |
Where research is gaining momentum
Research themes ranked by publication activity show where scientific interest is accelerating around this compound.
| # | Research topic | Papers |
|---|---|---|
| 1 | Nanoplatforms for cancer theranostics | 2 |
| 2 | Optical Imaging and Spectroscopy Techniques | 2 |
| 3 | S100 Proteins and Annexins | 2 |
| 4 | Cancer Research and Treatments | 1 |
| 5 | Cardiac Imaging and Diagnostics | 1 |
| 6 | Glycosylation and Glycoproteins Research | 1 |
| 7 | Lanthanide and Transition Metal Complexes | 1 |
| 8 | Lymphatic System and Diseases | 1 |
| 9 | Monoclonal and Polyclonal Antibodies Research | 1 |
| 10 | Nanoparticle-Based Drug Delivery | 1 |
Technology trend analysis
Cypris uses AI to connect emerging research themes to IP activity, commercialization signals, and underexplored opportunity areas.
See Cypris in actionWho's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | Andreas Faust | University of Münster | 9 |
| 2 | Christoph Bremer | University Hospital Münster | 9 |
| 3 | Alexei Bogdanov | Massachusetts General Hospital | 8 |
| 4 | Ick Chan Kwon | Korea Institute of Science and Technology | 8 |
| 5 | Anna Moore | Massachusetts General Hospital | 7 |
| 6 | Carsten Höltke | University Hospital Münster | 7 |
| 7 | Ralph Weissleder | Massachusetts General Hospital | 7 |
| 8 | Catherine Cannet | Novartis Institutes for BioMedical Research | 3 |
| 9 | Kwangmeyung Kim | Korea Institute of Science and Technology | 6 |
| 10 | Lee Josephson | Harvard University | 6 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| A multimodal nanoparticle for preoperative magnetic resonance imaging and intraoperative optical brain tumor delineation. | 2003 | 549 | Nanoplatforms for cancer theranostics |
| Tumor Paint: A Chlorotoxin:Cy5.5 Bioconjugate for Intraoperative Visualization of Cancer Foci | 2007 | 418 | Angiogenesis and VEGF in Cancer |
| Tumor-homing multifunctional nanoparticles for cancer theragnosis: Simultaneous diagnosis, drug delivery, and therapeutic monitoring | 2010 | 349 | Nanoparticle-Based Drug Delivery |
| Visualization of antitumor treatment by means of fluorescence molecular tomography with an annexin V–Cy5.5 conjugate | 2004 | 348 | Nanoplatforms for cancer theranostics |
| <b> <i>In vivo</i> </b> Near-Infrared Fluorescence Imaging of Integrin αvβ3 in Brain Tumor Xenografts | 2004 | 346 | Immunotherapy and Immune Responses |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the molecular composition of Cy5.5?
Which organizations hold the most patents involving Cy5.5?
What are the main research applications of Cy5.5 based on published literature?
Who are the most prolific researchers publishing on Cy5.5?
What is the patent landscape for Cy5.5 and recent trends?